Achilles Therapeutics to Present at Upcoming Conferences
May 03, 2022 08:00 ET
|
Achilles Therapeutics PLC
LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US
April 12, 2022 07:30 ET
|
Achilles Therapeutics PLC
– Expansion will supply clinical grade cNeT for ongoing Phase I/IIa clinical trials and support future development – LONDON, April 12, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:...
Achilles Therapeutics to Present at Upcoming Conferences
April 05, 2022 08:00 ET
|
Achilles Therapeutics PLC
LONDON, April 05, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting
April 04, 2022 08:00 ET
|
Achilles Therapeutics PLC
- Webcast will feature Professor Charles Swanton, TRACERx Chief Investigator and Achilles co-founder - - Panel will discuss how TRACERx real-world data enable Achilles’ AI-powered PELEUS...
Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
March 08, 2022 08:00 ET
|
Achilles Therapeutics PLC
LONDON, March 08, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Business Highlights
March 01, 2022 07:02 ET
|
Achilles Therapeutics PLC
- Patient data from higher dose cNeT as monotherapy and cNeT in combination with checkpoint inhibitor expected in 2H 2022 - - Strong cash position of $266 million supports clinical development and...
Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D.
February 07, 2022 07:30 ET
|
Achilles Therapeutics PLC
LONDON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Provides Business Update and Outlook for 2022
January 13, 2022 07:30 ET
|
Achilles Therapeutics PLC
LONDON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference
December 21, 2021 08:00 ET
|
Achilles Therapeutics PLC
LONDON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Added to the NASDAQ Biotechnology Index
December 20, 2021 08:00 ET
|
Achilles Therapeutics PLC
LONDON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...